CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...
Cardiovascular disease continues to be the leading cause of death worldwide. But advances in heart-failure therapeutics have ...
inews.co.uk on MSN
Covid jabs gave under-18s heart problems – but were less risky than catching virus
The health impact of a Covid infection was higher than the risks from the vaccine for teens and children - but it won't ...
Children and young people have higher risks of rare vascular and inflammatory diseases up to 12 months after a first COVID-19 ...
A large-scale MIT screen of tuberculosis proteins revealed several possible antigens that could be developed as a new vaccine for TB, the world’s deadliest infectious disease.
The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...
Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...
By activating an immune signaling pathway inside cancer cells, MIT researchers found a way to force tumors to produce a molecule that leads to their own destruction.
A stunning new study offers early evidence that Covid-19 vaccines might have a secret superpower: a precisely timed mRNA shot could help many cancer patients live longer.
ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...
Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.
The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback